X hits on this document

144 views

0 shares

0 downloads

0 comments

14 / 49

1988

Circulation

November 9, 2010

thrombolytic therapy and angioplasty, has resulted in a

marked improvement in patient outcomes.237–239

Our diag-

nostic, treatment, and disposition decision making has changed dramatically over the past 20 years, resulting in many patients with low-risk ACS features being evaluated and discharged either directly from the ED or after a brief stay in an ED-based observation unit. Given the complex- ity of AHFS patients, the pathophysiologic target is likely

multifactorial, but we need a systematic approach to understanding the interaction between AHFS management decisions and their impact on outcomes. As the number of patients with HF and AHFS continues to grow, it is imperative that ongoing therapeutic trials and management strategies address the significant knowledge gaps that currently exist in AHFS care if we expect to deliver evidence-based care and improve clinical outcomes.

Allen S. Anderson

University of Chicago Medical Center

None

None

Johnson & Johnson/Scios*

Medical malpractice case review on cardiac transplant prognosis*

None

None

None

Cynthia Arslanian- Engoren

University of Michigan School of Nursing

Blue Cross Blue Shield of Michigan†

None

None

None

None

None

None

Gary S. Francis

University of Minnesota

None

None

None

None

None

Sanofi-Aventis*

DSMBs for Novartis*; Corthera*

Mihai Gheorghiade

Northwestern University

None

None

None

None

None

Bayer Schering Pharma AG†; DebioPharm S.A.†; Medtronic†; Novartis Pharma AG†; Otsuka Pharmaceuticals†; Sigma Tau†; Solvay Pharmaceuticals†; PeriCor Therapeutics†

None

W. Brian Gibler

University of Cincinnati College of Medicine

AstraZeneca†; Bristol-Myers Squibb†; Sanofi-Aventis†; Schering Plough†

None

None

None

Inovise*

AstraZeneca*; Daiichi Sankyo/Lilly*; Schering Plough*

None

Phillip D. Levy

Wayne State University

Astellas Pharm Inc.*; Corthera Inc.*; Nile Therapeutics*; Solvay Pharmaceuticals*

None

The Society of Chest Pain Centers*

None

None

Bayer Schering Pharma AG*; Corthera, Inc*; EKR Therapeutics*; The Medicines Co.*

None

James K. McCord

Henry Ford Health System

Brahms Diagnostic*; Nanosphere*; Siemens*

None

Biosite Diagnostics*

None

None

None

None

Peter S. Pang

Northwestern Memorial Faculty Foundation

Merck†

None

Corthera Inc.*; Supplement sponsored by Otsuka and Abbott*; The Society of Chest Pain Centers*

Provided expert witness review of a case involving sepsis management (1 case only)

None

Astellas†; Bayer†* Johnson & Johnson*; Palatin Technologies*; PeriCor Therapeutics*; Solvay Pharmaceuticals†

DSMB for the Medicines Co.*

Mark B. Parshall

University of New Mexico

None

None

None

None

None

None

None

Writing Group Member

Employment

Neal L. Weintraub Sean P. Collins

University of Cincinnati University of Cincinnati

Expert Witness

Ownership Interest

Consultant/Advisory Board

None None

None None

None

Abbott Point of Care*; Bayer Pharmaceuticals*; The Medicines Co.*

Other

None None

Writing Group Disclosures

Other

Speakers’

Research

Bureau/

Support

Honoraria

None

None

None

None

Research Grant None

Abbott Point of Care†; Brahms Diagnostics*; NIH/NHLBI†

Disclosures

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

*Modest.

  • Significant.

Downloaded from http://circ.ahajournals.org/ by guest on February 5, 2015

Document info
Document views144
Page views144
Page last viewedFri Dec 09 11:46:44 UTC 2016
Pages49
Paragraphs1916
Words46879

Comments